GO:0061534 gamma-aminobutyric acid secretion, neurotransmission: Synaptic Inhibition, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061534 describes the regulated release of gamma-aminobutyric acid (GABA) by a cell, where GABA acts as a neurotransmitter.
• GABA is the principal inhibitory neurotransmitter in the mammalian central nervous system, and its secretion is essential for balancing excitation and preventing hyperexcitability.
• Dysregulation of GABA secretion and neurotransmission is implicated in anxiety disorders, major depressive disorder, epilepsy, cerebral ischemia, and stiff-person syndrome.
• Key molecular players include GABA-synthesizing enzymes (GAD1, GAD2), vesicular transporters (SLC32A1), plasma membrane transporters (SLC6A1, SLC6A11, SLC6A12, SLC6A13), and both ionotropic (GABAA) and metabotropic (GABAB) receptors.
• GABA secretion can be modulated by presynaptic GABAA receptors, glutamatergic inputs via GluD1, and pharmacological agents such as ketamine.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of GABAergic genes in health and disease.
Description
Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the vertebrate central nervous system, and its regulated secretion is fundamental for controlling neuronal excitability. The Gene Ontology term GO:0061534, gamma-aminobutyric acid secretion, neurotransmission, captures the biological process by which a cell releases GABA so that it can act as a neurotransmitter. This process is distinct from general GABA metabolism because it specifically refers to the regulated, vesicular or non-vesicular release of GABA that enables synaptic and extrasynaptic signaling. Understanding GO:0061534 is critical for neurobiologists because inhibitory neurotransmission shapes circuit function, and its disruption is linked to a wide range of neurological and psychiatric conditions. For example, altered GABAergic inhibition in the amygdala contributes to anxiety circuitry dysfunction, while impaired GABA neurotransmission is observed in major depressive disorder and in Kcnq2-related early onset epilepsy. Moreover, autoimmune targeting of GABAergic proteins underlies stiff-person syndrome, a disorder characterized by impaired GABA neurotransmission. Researchers studying GO:0061534 therefore need robust experimental models to manipulate and measure GABA release, including genetic knockouts, point mutations, and fluorescent reporters. This article provides a research-grade overview of the ontology, molecular machinery, disease relevance, and CRISPR-based methods for investigating gamma-aminobutyric acid secretion, neurotransmission.
gamma-aminobutyric acid secretion, neurotransmission At A Glance
| GO ID | GO:0061534 |
|---|---|
| GO term | gamma-aminobutyric acid secretion, neurotransmission |
| Ontology | biological_process |
| Synonym | none |
| Major function | Regulated release of GABA for inhibitory neurotransmission |
| Cellular location | Presynaptic terminals, axons, and GABAergic neurons |
| Key transporters | SLC32A1 (VGAT), SLC6A1 (GAT1), SLC6A11 (GAT3), SLC6A12 (BGT1), SLC6A13 (GAT2) |
| Key receptors | GABAA (ionotropic), GABAB (metabotropic), and presynaptic GABAA receptors |
| Associated diseases | Anxiety, major depressive disorder, epilepsy, cerebral ischemia, stiff-person syndrome |
What Is GO:0061534?
GO:0061534, gamma-aminobutyric acid secretion, neurotransmission, is defined by the Gene Ontology as the regulated release of gamma-aminobutyric acid by a cell, in which the gamma-aminobutyric acid acts as a neurotransmitter. In other words, it is the process that packages, transports, and releases GABA so that it can bind to receptors on target cells and mediate inhibitory signaling.
Why Is gamma-aminobutyric acid secretion, neurotransmission Important in Cell Biology?
GO:0061534 is important because GABAergic inhibition is the primary brake on neuronal excitation, and its dysregulation leads to network hyperexcitability, seizures, anxiety, and mood disorders. Experimental manipulation of GABA secretion is therefore central to understanding both normal brain function and disease mechanisms.
• GABA is the main inhibitory neurotransmitter, and its secretion maintains excitation-inhibition balance.
• Altered GABA secretion in the amygdala is linked to anxiety disorders.
• Impaired GABA neurotransmission is observed in major depressive disorder and is influenced by serotonergic antidepressants.
• Kcnq2 mutations cause early onset epilepsy with abnormal GABA neurotransmission.
• Cerebral ischemia disrupts GABAA neurotransmission, contributing to excitotoxicity.
• Stiff-person syndrome is an autoimmune disorder affecting GABA neurotransmission.
• Presynaptic GABAA receptors can modulate GABA release, providing a feedback mechanism.
• GluD1 binds GABA and controls inhibitory plasticity, linking GABA secretion to synaptic remodeling.
• Ketamine inhibits GABA and glycine neurotransmission to cardiac vagal neurons, showing pharmacological sensitivity.
• CRISPR models enable causal testing of GABAergic genes in these disease contexts.
What Happens During gamma-aminobutyric acid secretion, neurotransmission?
GABA synthesis and vesicular packaging
In simple terms: GABA is made inside the neuron and packed into small bubbles called vesicles.
GABA is synthesized primarily by the enzymes GAD1 and GAD2, which decarboxylate glutamate. Newly synthesized GABA is then loaded into synaptic vesicles by the vesicular GABA transporter SLC32A1 (VGAT), a process that requires a proton gradient. This packaging step is essential for regulated secretion because it concentrates GABA for subsequent release.
Vesicle fusion and GABA release
In simple terms: When a signal arrives, the vesicles fuse with the membrane and dump GABA outside.
Upon action potential arrival and calcium influx, synaptic vesicles fuse with the presynaptic membrane and release GABA into the synaptic cleft. This exocytotic release is the core event of GO:0061534 and allows GABA to act on postsynaptic and presynaptic receptors. The released GABA can then bind to GABAA and GABAB receptors to mediate fast and slow inhibition, respectively.
Presynaptic modulation of GABA release
In simple terms: The neuron can adjust how much GABA it releases based on feedback signals.
Presynaptic GABAA receptors can modulate GABA release, providing a feedback mechanism that fine-tunes inhibitory output. Additionally, GluD1, a glutamate receptor-like protein, binds GABA and controls inhibitory plasticity, suggesting that GABA secretion is dynamically regulated by multiple receptor systems. This modulation is critical for adapting inhibition to changing network activity.
GABA reuptake and termination of signaling
In simple terms: After release, GABA is taken back up into cells to stop the signal.
GABA transporters such as SLC6A1 (GAT1), SLC6A11 (GAT3), SLC6A12 (BGT1), and SLC6A13 (GAT2) remove GABA from the synaptic cleft, terminating neurotransmission. This reuptake is essential for maintaining low extracellular GABA levels and for recycling the neurotransmitter. Dysfunction of these transporters can lead to altered inhibitory tone and disease.
Key Genes Involved in GO:0061534 gamma-aminobutyric acid secretion, neurotransmission
The following genes and proteins are central to gamma-aminobutyric acid secretion, neurotransmission, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GAD1 | Synthesizes GABA from glutamate | Target for knockout to reduce GABA production |
| GAD2 | Synthesizes GABA from glutamate | Isoform-specific roles in GABA secretion |
| SLC32A1 | Vesicular GABA transporter (VGAT) | Essential for vesicular packaging and release |
| SLC6A1 | Plasma membrane GABA transporter GAT1 | Regulates reuptake and inhibitory tone |
| SLC6A11 | GABA transporter GAT3 | Astrocytic GABA uptake |
| SLC6A12 | GABA transporter BGT1 | Non-neuronal GABA transport |
| SLC6A13 | GABA transporter GAT2 | GABA clearance in specific regions |
| GABRA1 | GABAA receptor alpha1 subunit | Mediates fast inhibitory neurotransmission |
| GABRB2 | GABAA receptor beta2 subunit | Receptor assembly and function |
| GABRG2 | GABAA receptor gamma2 subunit | Synaptic localization and benzodiazepine sensitivity |
| GABBR1 | GABAB receptor subunit 1 | Metabotropic inhibition |
| GABBR2 | GABAB receptor subunit 2 | Metabotropic inhibition |
| KCNQ2 | Potassium channel subunit | Mutations cause early onset epilepsy with abnormal GABA neurotransmission |
| GAD65 | Autoantigen in stiff-person syndrome | Autoimmune target affecting GABA neurotransmission |
| GluD1 | Binds GABA and controls inhibitory plasticity | Novel regulator of GABAergic synapses |
| nAChR | Nicotinic acetylcholine receptor | Ketamine inhibits GABA/glycine neurotransmission to cardiac vagal neurons |
| GABAA receptors | Ionotropic GABA receptors | Presynaptic modulation of GABA release |
How Is gamma-aminobutyric acid secretion, neurotransmission Regulated?
Gamma-aminobutyric acid secretion, neurotransmission is regulated at multiple levels. Presynaptic GABAA receptors provide feedback inhibition of GABA release. GluD1 acts as a GABA-binding protein that controls inhibitory plasticity, thereby regulating the strength of GABAergic synapses. Additionally, serotonergic antidepressants can influence GABA neurotransmission, suggesting that neuromodulatory systems regulate this process. Ketamine has been shown to inhibit GABA and glycine neurotransmission to cardiac vagal neurons, indicating pharmacological regulation.
gamma-aminobutyric acid secretion, neurotransmission and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GAD1/GAD2 | Reduced GABA synthesis in epilepsy and anxiety | Knockout or point-mutation mice |
| SLC6A1 | GABA transporter dysfunction in epilepsy | Knockout or knock-in models |
| KCNQ2 | Early onset epilepsy with abnormal GABA neurotransmission | Kcnq2 mutant knock-in |
| GAD65 | Stiff-person syndrome (autoimmune) | Autoantibody transfer or GAD65 knockout |
| GABRA1 | Cerebral ischemia and epilepsy | Point-mutation knock-in |
Anxiety disorders and amygdala circuitry
Inhibition in the amygdala anxiety circuitry is critically dependent on GABAergic neurotransmission, and disruption of GABA secretion in this region is associated with anxiety disorders. Studies in animal models show that altered GABA release can shift the balance between fear and safety learning.
Major depressive disorder
Altered gamma-aminobutyric acid neurotransmission has been reported in major depressive disorder, and serotonergic antidepressants can influence GABAergic function. This suggests that GABA secretion is a potential biomarker and therapeutic target in depression.
Epilepsy and KCNQ2-related disorders
Abnormal GABA neurotransmission is observed in a Kcnq2 model of early onset epilepsy, linking potassium channel dysfunction to impaired inhibition. This highlights the importance of GABA secretion in seizure susceptibility.
Cerebral ischemia and stiff-person syndrome
GABAA neurotransmission is disrupted in cerebral ischemia, contributing to excitotoxic injury. In stiff-person syndrome, autoantibodies against GAD65 impair GABA neurotransmission, leading to muscle stiffness and spasms.
From gamma-aminobutyric acid secretion, neurotransmission-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GAD1 reduce GABA secretion? | GAD1 knockout cell line or mouse |
| Does a KCNQ2 mutation alter GABA release? | Kcnq2 point-mutation knock-in |
| Can we visualize GABA release in real time? | Knock-in of fluorescent reporter into SLC32A1 |
| Does overexpression of GAT1 reduce inhibitory tone? | Overexpression of SLC6A1 in neurons |
| Does GluD1 regulate inhibitory plasticity? | GluD1 knockout or point mutant |
| Does ketamine affect GABA neurotransmission? | Pharmacological treatment in cardiac vagal neuron models |
How to Study the gamma-aminobutyric acid secretion, neurotransmission Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Patch-clamp electrophysiology | IPSCs and GABA release probability | Assessing inhibitory synaptic strength |
| Fluorescent GABA sensors | Real-time GABA concentration | Imaging release in vivo |
| Immunohistochemistry | GABAergic synapse density | Validating knockout models |
| In situ hybridization | mRNA expression of GABAergic genes | Mapping GAD1/GAD2 expression |
| Western blot | Protein levels of GAD, VGAT, GATs | Quantifying knockout efficiency |
| CRISPR knockout | Loss of gene function | Causal testing of GABA genes |
| CRISPR knock-in | Reporter or mutation introduction | Tracking GABA release |
| Pharmacological infusion | Acute modulation of GABA secretion | Testing drugs like ketamine |
Electrophysiology
Patch-clamp recordings of inhibitory postsynaptic currents (IPSCs) measure GABA release and receptor function in real time. This method is the gold standard for assessing GABAergic neurotransmission.
Fluorescent GABA sensors
Genetically encoded GABA sensors such as iGABASnFR allow imaging of GABA release dynamics in living tissue. These sensors can be targeted to specific cell types using CRISPR knock-in.
Immunohistochemistry and imaging
Antibodies against GAD65/67, VGAT, and GABA receptors visualize the distribution of GABAergic synapses. This is useful for validating knockout or knock-in models.
Pharmacological and genetic manipulation
Drugs like ketamine or GABA transporter inhibitors can acutely modulate GABA secretion. Genetic tools such as CRISPR knockout provide chronic manipulation.
How CRISPR Can Be Used to Study GO:0061534 gamma-aminobutyric acid secretion, neurotransmission
Knockout
CRISPR knockout of GABAergic genes such as GAD1, GAD2, or SLC32A1 can abolish or reduce GABA secretion, allowing causal testing of their role in inhibitory neurotransmission. Knockout models are also used to study epilepsy-related genes like KCNQ2.
Point Mutation
Point mutations in genes like KCNQ2 or GABRA1 can be introduced using CRISPR to model human disease variants that alter GABA secretion. These models help dissect subtle effects on receptor function or transporter activity.
Knock-in
Knock-in of fluorescent reporters (e.g., iGABASnFR) or tags into endogenous loci enables real-time visualization of GABA release without overexpression artifacts. Knock-in of disease mutations also provides physiologically relevant models.
Overexpression
Overexpression of GABA transporters like SLC6A1 or enzymes like GAD1 can increase or decrease inhibitory tone, depending on the gene. This approach is useful for gain-of-function studies and for testing rescue strategies.
How EDITGENE Supports gamma-aminobutyric acid secretion, neurotransmission Research
Researchers studying gamma-aminobutyric acid secretion, neurotransmission-related genes often need to determine whether a candidate gene is causally involved in GABA release, receptor function, or disease pathogenesis. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell and animal models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for gamma-aminobutyric acid secretion, neurotransmission research.
Frequently Asked Questions About gamma-aminobutyric acid secretion, neurotransmission
What is GO:0061534?
GO:0061534 is the Gene Ontology term for gamma-aminobutyric acid secretion, neurotransmission, defined as the regulated release of GABA by a cell where GABA acts as a neurotransmitter.
What genes are involved in gamma-aminobutyric acid secretion, neurotransmission?
Key genes include GAD1, GAD2, SLC32A1, SLC6A1, SLC6A11, SLC6A12, SLC6A13, GABRA1, GABRB2, GABRG2, GABBR1, GABBR2, KCNQ2, and GluD1.
How is GABA secreted?
GABA is synthesized by GAD enzymes, packaged into vesicles by SLC32A1, and released via calcium-dependent exocytosis.
What diseases are linked to abnormal GABA secretion?
Anxiety disorders, major depressive disorder, epilepsy, cerebral ischemia, and stiff-person syndrome are linked to altered GABA neurotransmission.
What is the role of GABAA receptors in GABA secretion?
Presynaptic GABAA receptors can modulate GABA release, providing feedback regulation.
How does ketamine affect GABA neurotransmission?
Ketamine inhibits inspiratory-evoked GABA and glycine neurotransmission to cardiac vagal neurons.
What is the role of GluD1 in GABA secretion?
GluD1 binds GABA and controls inhibitory plasticity, regulating GABAergic synapse strength.
How can I study GABA secretion in the lab?
Methods include patch-clamp electrophysiology, fluorescent GABA sensors, immunohistochemistry, and CRISPR-based genetic manipulation.
What CRISPR models are available for GABA research?
Knockout, point mutation, knock-in, and overexpression models can be generated for GABAergic genes.
Why is GABA secretion important for brain function?
GABA is the main inhibitory neurotransmitter, and its secretion maintains excitation-inhibition balance critical for normal brain function.
Conclusion
GO:0061534, gamma-aminobutyric acid secretion, neurotransmission, is a fundamental biological process that governs inhibitory signaling in the nervous system. Its dysregulation contributes to anxiety, depression, epilepsy, ischemia, and autoimmune disorders. Understanding the molecular machinery and regulation of GABA release is essential for developing targeted therapies. CRISPR-based models from EDITGENE provide powerful tools to dissect these mechanisms and accelerate discovery.
References
- 1. Babaev O et al.. 2018. Inhibition in the amygdala anxiety circuitry.. Exp Mol Med 50(4):1-16 PMID: 29628509
- 2. Schwartz-Bloom RD et al.. 2001. gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia.. J Neurochem 77(2):353-71 PMID: 11299298
- 3. Piot L et al.. 2023. GluD1 binds GABA and controls inhibitory plasticity.. Science 382(6677):1389-1394 PMID: 38060673
- 4. Pehrson AL et al.. 2015. Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.. Drug Des Devel Ther 9:603-24 PMID: 25653499
- 5. Uchida T et al.. 2017. Abnormal γ-aminobutyric acid neurotransmission in a Kcnq2 model of early onset epilepsy.. Epilepsia 58(8):1430-1439 PMID: 28575529
- 6. Levy LM et al.. 1999. The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid.. Ann Intern Med 131(7):522-30 PMID: 10507962
- 7. Trigo FF et al.. 2008. Axonal GABAA receptors.. Eur J Neurosci 28(5):841-8 PMID: 18691324
- 8. Wang X et al.. 2005. Ketamine inhibits inspiratory-evoked gamma-aminobutyric acid and glycine neurotransmission to cardiac vagal neurons in the nucleus ambiguus.. Anesthesiology 103(2):353-9 PMID: 16052118
